DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Myelodysplastic Syndrome (MDS)” report has been
added to ResearchAndMarkets.com’s offering.
This Market Spotlight report covers the myelodysplastic syndrome market,
comprising key marketed and pipeline drugs, recent events and analyst
opinion, clinical trials, probability of success, upcoming events,
patent information, a 10-year disease incidence forecast, and licensing
and acquisition deals, as well as presenting drug-specific revenue
forecasts
Key Takeaways
-
The estimates that in 2017, there were 367,200 incident cases of
myelodysplastic syndrome (MDS) worldwide, and forecasts that number to
increase to 401,700 incident cases by 2026. -
Approved drugs in the MDS space target DNA methyltransferase, BCR-ABL
fusion protein, KIT/c-KIT, platelet-derived growth factor receptor,
erythropoietin receptor, angiogenesis, E3 ubiquitin ligase, and the
immune system. These therapies are administered via the intravenous,
oral, and subcutaneous routes. -
The greatest proportion of industry-sponsored drugs in active clinical
development for MDS are in Phase II. Therapies in development for MDS
focus on a wide variety of targets. The majority of pipeline drugs in
the MDS space are administered via the intravenous or oral routes,
with the remainder being subcutaneous or intradermal formulations. -
High-impact upcoming events for drugs in the MDS space comprise
topline Phase II and Phase III trial results. The overall likelihood
of approval of a Phase I hematologic asset is 10.7%, and the average
probability a drug advances from Phase III is 57.6%. Drugs, on
average, take 8.7 years from Phase I to approval, compared to 9.2
years in the overall oncology space. -
There have been 18 licensing and asset acquisition deals involving MDS
drugs during 2014-19. The $1.8bn exclusive global collaboration and
license agreement made in December 2018 between Argenx and Cilag to
evaluate cusatuzumab (ARGX-110), an anti-CD70 SIMPLE Antibody, in
acute myeloid leukemia (AML), high-risk MDS, and other hematological
malignancies was the largest deal during the period. -
The distribution of clinical trials across Phase I-IV indicates that
the vast majority of trials for MDS have been in the early and
mid-phases of development, with 89% of trials in Phase I-II, and only
11% in Phase III-IV. -
The US has a substantial lead in the number of MDS clinical trials
globally. France leads the major EU markets, while Japan has the top
spot in Asia. -
Clinical trial activity in the MDS space is dominated by completed
trials. Celgene has the highest number of completed clinical trials
for MDS, with 91 trials. -
Celgene leads the industry sponsors with by far the highest number of
clinical trials for MDS.
Key Topics Covered:
OVERVIEW
KEY TAKEAWAYS
DISEASE BACKGROUND
MDS subtypes
TREATMENT
Supportive therapy
Growth factors
Chemotherapy
Immune treatments
Stem cell transplant
EPIDEMIOLOGY
MARKETED DRUGS
PIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
Luspatercept for MDS (December 2, 2018)
Luspatercept for MDS (June 28, 2018)
Imetelstat for MDS (July 31, 2017)
KEY UPCOMING EVENTS
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
Impressive Clinical Results For Argenx’s Oncology Candidate Seal The
Deal for Janssen
Onconova Grants Latin American Rigosertib Rights To Pint Pharma
PARENT PATENTS
REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
Recent events
BIBLIOGRAPHY
Prescription information
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/7jo1ve
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Leukemia
Drugs